Latest Insider Transactions at Hca Healthcare, Inc. (HCA)
This section provides a real-time view of insider transactions for Hca Healthcare, Inc. (HCA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HCA Healthcare, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HCA Healthcare, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 09
2024
|
Erol R Akdamar Group President |
SELL
Bona fide gift
|
Direct |
5,139
-100.0%
|
-
|
|
May 09
2024
|
Jeffrey E. Cohen SVP-Government Relations |
SELL
Open market or private sale
|
Direct |
1,650
-24.14%
|
$516,450
$313.0 P/Share
|
|
May 09
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
6,311
-17.56%
|
$1,994,276
$316.88 P/Share
|
|
May 08
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Bona fide gift
|
Direct |
4,500
-11.13%
|
-
|
|
May 07
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,349
-23.4%
|
$3,877,586
$314.45 P/Share
|
|
May 07
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,660
+26.12%
|
$2,593,740
$139.06 P/Share
|
|
May 06
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
1,600
-4.48%
|
$494,400
$309.0 P/Share
|
|
May 03
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
890
-3.98%
|
$277,680
$312.0 P/Share
|
|
May 02
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
973
-4.17%
|
$303,576
$312.0 P/Share
|
|
May 01
2024
|
Mike A Marks EVP and CFO |
SELL
Bona fide gift
|
Direct |
566
-20.19%
|
-
|
|
Apr 29
2024
|
Thomas F Frist Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,284
+8.69%
|
-
|
|
Apr 29
2024
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
610
+2.86%
|
-
|
|
Apr 29
2024
|
Hugh F Johnston Director |
BUY
Grant, award, or other acquisition
|
Direct |
610
+18.77%
|
-
|
|
Apr 29
2024
|
Michael W Michelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,091
+9.43%
|
-
|
|
Apr 29
2024
|
Wayne Joseph Riley Director |
BUY
Grant, award, or other acquisition
|
Direct |
610
+4.21%
|
-
|
|
Apr 29
2024
|
Andrea B Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
610
+14.8%
|
-
|
|
Apr 29
2024
|
William R Frist Director |
BUY
Grant, award, or other acquisition
|
Direct |
963
+7.48%
|
-
|
|
Apr 29
2024
|
Meg Crofton Director |
BUY
Grant, award, or other acquisition
|
Direct |
610
+8.79%
|
-
|
|
Apr 29
2024
|
Robert J Dennis Director |
BUY
Grant, award, or other acquisition
|
Direct |
963
+3.63%
|
-
|
|
Mar 20
2024
|
Chad J Wasserman SVP and CIO |
SELL
Open market or private sale
|
Direct |
876
-35.73%
|
$289,080
$330.25 P/Share
|
|
Mar 18
2024
|
Chad J Wasserman SVP and CIO |
SELL
Open market or private sale
|
Direct |
344
-12.3%
|
$110,424
$321.97 P/Share
|
|
Mar 18
2024
|
Chad J Wasserman SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,224
-30.45%
|
$400,248
$327.17 P/Share
|
|
Mar 18
2024
|
Chad J Wasserman SVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,100
+34.31%
|
$212,100
$101.16 P/Share
|
|
Feb 16
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,005
-31.93%
|
$617,540
$308.55 P/Share
|
|
Feb 16
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,280
+50.0%
|
-
|
|
Feb 16
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,976
-7.81%
|
$608,608
$308.55 P/Share
|
|
Feb 16
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
BUY
Grant, award, or other acquisition
|
Direct |
5,020
+16.55%
|
-
|
|
Feb 16
2024
|
Chad J Wasserman SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
499
-20.63%
|
$153,692
$308.55 P/Share
|
|
Feb 16
2024
|
Chad J Wasserman SVP and CIO |
BUY
Grant, award, or other acquisition
|
Direct |
2,040
+45.75%
|
-
|
|
Feb 16
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,023
-7.48%
|
$315,084
$308.55 P/Share
|
|
Feb 16
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+21.65%
|
-
|
|
Feb 16
2024
|
Christopher F. Wyatt SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,976
-4.66%
|
$608,608
$308.55 P/Share
|
|
Feb 16
2024
|
Christopher F. Wyatt SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
5,020
+10.59%
|
-
|
|
Feb 16
2024
|
Phillip G Billington SVP-Internal Audit Services |
SELL
Payment of exercise price or tax liability
|
Direct |
1,022
-1.91%
|
$314,776
$308.55 P/Share
|
|
Feb 16
2024
|
Phillip G Billington SVP-Internal Audit Services |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+6.58%
|
-
|
|
Feb 16
2024
|
Jeffrey E. Cohen SVP-Government Relations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,359
-16.59%
|
$418,572
$308.55 P/Share
|
|
Feb 16
2024
|
Jeffrey E. Cohen SVP-Government Relations |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+31.57%
|
-
|
|
Feb 16
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,212
-14.82%
|
$1,913,296
$308.55 P/Share
|
|
Feb 16
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,980
+17.32%
|
-
|
|
Feb 16
2024
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,950
-21.42%
|
$1,832,600
$308.55 P/Share
|
|
Feb 16
2024
|
Jon M Foster EVP and COO |
BUY
Grant, award, or other acquisition
|
Direct |
16,320
+37.01%
|
-
|
|
Feb 16
2024
|
Richard A Hammett Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,762
-8.95%
|
$542,696
$308.55 P/Share
|
|
Feb 16
2024
|
Richard A Hammett Group President |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+21.83%
|
-
|
|
Feb 16
2024
|
Samuel N Hazen CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
30,387
-10.26%
|
$9,359,196
$308.55 P/Share
|
|
Feb 16
2024
|
Samuel N Hazen CEO |
BUY
Grant, award, or other acquisition
|
Direct |
78,440
+20.94%
|
-
|
|
Feb 16
2024
|
Mike A Marks EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,022
-26.72%
|
$314,776
$308.55 P/Share
|
|
Feb 16
2024
|
Mike A Marks EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
3,780
+49.7%
|
-
|
|
Feb 16
2024
|
Timothy M Mc Manus Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,002
-7.87%
|
$616,616
$308.55 P/Share
|
|
Feb 16
2024
|
Timothy M Mc Manus Group President |
BUY
Grant, award, or other acquisition
|
Direct |
6,280
+19.81%
|
-
|
|
Feb 16
2024
|
Sammie S Mosier SVP & Chief Nurse Executive |
SELL
Payment of exercise price or tax liability
|
Direct |
1,068
-9.31%
|
$328,944
$308.55 P/Share
|